CLNN Stock Summary and Trading Ideas (Clene | NASDAQ:CLNN)

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Clene trades on the NASDAQ stock market under the symbol CLNN.

As of October 23, 2026, CLNN stock price was flat at $3.88 with 20,321 million shares trading.

CLNN has a beta of 2.30, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.07 to the broad based SPY ETF.

CLNN has a market cap of $55.15 million. This is considered a Micro Cap stock.

Last quarter Clene reported $90,000 in Revenue and -$1.08 earnings per share. This beat revenue expectation by $36,960 and missed earnings estimates by -$.80.

In the last 3 years, CLNN traded as high as $13.50 and as low as $2.28.

The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF, IWC.

CLNN has underperformed the market in the last year with a return of -52.4%, while the SPY ETF gained +14.3%. In the last 3 month period, CLNN fell short of the market, returning -29.2%, while SPY returned +3.2%. However, in the most recent 2 weeks CLNN has outperformed the stock market by returning +0.5%, while SPY returned -2.4%.

CLNN support price is $3.65 and resistance is $4.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.